Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 400 Shares of Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 400 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $30.00, for a total transaction of $12,000.00. Following the sale, the chief financial officer directly owned 11,223 shares of the company’s stock, valued at approximately $336,690. The trade was a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $15,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $29.51 on Thursday. The stock has a 50 day moving average price of $30.26 and a two-hundred day moving average price of $28.40. The firm has a market capitalization of $1.71 billion, a P/E ratio of -12.72 and a beta of 0.39. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, equities analysts forecast that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CAPR. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. Piper Sandler reiterated an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. B. Riley Financial increased their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $50.30.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently bought and sold shares of the business. Creek Drive Management Group LLC bought a new position in Capricor Therapeutics in the 4th quarter valued at $1,039,000. Moody Aldrich Partners LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth $6,025,000. Pier Capital LLC raised its stake in shares of Capricor Therapeutics by 35.0% during the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after purchasing an additional 128,837 shares during the period. UBS Group AG boosted its holdings in shares of Capricor Therapeutics by 91.0% in the 4th quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock worth $6,875,000 after buying an additional 113,499 shares during the last quarter. Finally, HBK Sorce Advisory LLC boosted its holdings in shares of Capricor Therapeutics by 19.4% in the 4th quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company’s stock worth $5,879,000 after buying an additional 33,128 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.